Sheila M. Hegde

Featured in: Favicon

jamanetwork.com Favicon

onlinelibrary.wiley.com

Articles

Time to Clinical Benefit of Dapagliflozin in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical Trial | Cardiology | JAMA Cardiology | JAMA Network

Oct 31, 2024 | jamanetwork.com | Brian Claggett |Kansas City |Felipe Martinez |Sheila M. Hegde

Key PointsQuestion When are the clinical benefits of the sodium glucose cotransporter 2 inhibitor dapagliflozin first apparent among patients with heart failure with mildly reduced or preserved ejection fraction?

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →